MYGN - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Myriad Genetics, Inc.

Stable demand for genetic diagnostics, which remains independent of economic conditions, serves as the primary driver for Myriad Genetics, Inc. (MYGN). Annual revenue dynamics on a TTM basis clearly confirm this resilience, with the -2.60 mark reflecting the current state of the business. However, geopolitical tensions are limiting access to reagents, while the current focus on organic growth and local partnerships is replacing the previous strategy of active acquisitions.
פילוחי נתונים אנליטיים מרוכזים עבור Myriad Genetics (MYGN)

This metric measures the percentage change in revenue over the last 12 months relative to the same period last year, reflecting the pace of market share expansion and the fundamental resilience of the business. Amid pricing pressure from DTC startups and risks of insurance reimbursement revisions, the year-over-year (LTM) gross revenue trend demonstrates the ability of Myriad Genetics, Inc. (MYGN) to maintain its position in the highly competitive genetic testing segment.